The primary objective of the study was to investigate the risk factors for Histoplasma capsulatum fungemia. We conducted a retrospective case-control study among patients with histoplasmosis seen at Mayo Clinic in Rochester from 1 January 1991 through 31 December 2005. Blood cultures were prepared from specimens obtained from 111 patients with a diagnosis of histoplasmosis of which 55 had demonstrated H. capsulatum fungemia whereas the cultures of the remaining 56 patients were negative. The mean age of the patients was 56 years, of which 70% men and 95% were white. In univariate analysis, immunocompromised status (OR 2.9, P ϭ0.008), peripheral leukocyte count (WBC) 3000 cells/mm 3 (OR 7.3, P Ͻ0.001), albuminϽ3.5 g/ dl (OR 3.1, P ϭ0.018), and Charlson score of Ͼ4 (OR 2.9, P ϭ0.022) were associated with H. capsulatum fungemia, but age Ͼ55 years was not (OR 1.4, P ϭ0.38). In multivariable analysis, immunocompromised status (OR 2.4, P ϭ0.043) and WBCϽ3000 cells/mm 3 (OR 6.5, P ϭ0.001) remained signifi cant factors associated with H. capsulatum fungemia. Immunocompromised status and WBCϽ3000 cells/mm 3 are independent risk factors for the development of H. capsulatum fungemia.
Patients and methods
The study included adult patients (ageՆ18 years) with a diagnosis of histoplasmosis seen between 1 January 1991 and 31 December 2005 who had lysis centrifugation fungal blood cultures drawn prior to the initiation of antifungal therapy. Cases included patients with H. capsulatum fungemia and controls who had negative fungal blood cultures. The case diagnosis was per patient and not per occurrence. A diagnosis of histoplasmosis was based on any of the following criteria: a positive lysis centrifugation blood, bone marrow, body fl uid, or tissue culture for H. capsulatum var. capsulatum ; histopathologic or direct microscopic demonstration of morphological forms consistent with H. capsulatum; a positive urine, serum, or cerebrospinal fl uid
Introduction
Histoplasmosis is the most prevalent endemic mycosis in the United States. Most infections are asymptomatic or self-limited, but one in 2000 acute infections, often in immunocompromised hosts, results in severe and progressive dissemination [ 1, 2 ] .
A variety of conditions predispose to disseminated histoplasmosis (DH). A landmark study published in 1982 showed after stratifi cation that both age Ͼ54 years and immunocompromise status were risk factors for dissemination [ 3 ] . Over the past two decades, human immunodeficiency virus (HIV) has been well-recognized as an additional risk factor for DH [ 4 -7 ] . Numerous other publications have linked a variety of immunocompromised conditions to the development of either histoplasmosis or DH. These include solid organ transplantation [ 8 ,9 ] , an area under the curve of 0.7 consistent with a good discriminative property for the model. The Kaplan Meier method was used to perform the survival analysis using a log rank test to compare the survival curves ( Fig. 1 ) .
Results
Four hundred and thirty-eight patients fulfi lled the diagnostic criteria for histoplasmosis. Of these, 111 had at least one blood sample drawn for fungal culture prior to the initiation of antifungal therapy. We found that cultures were positive for 55 patients indicating H. capsulatum fungemia (cases) but negative for the remaining 56 patients (controls). The 55 cases and 29 of the 56 controls were previously described in a review of systemic histoplasmosis [ 15 ] . A mean of 2.2 and a median of 2 fungal blood cultures were initiated among patients with proven Histoplasma fungemia. Patients with negative fungal blood cultures had a mean of 1.5 and a median of 2 fungal blood cultures. Therefore, the 2 groups had a comparable number of fungal blood cultures drawn.
Baseline characteristics are described in Table 1 which indicate that the mean age of patients was 56 years, of whom 70% were males and 95% Caucasians. Cases and controls had comparable age, ethnicity and gender. Signifi cantly more patients with H. capsulatum fungemia were immunocompromised (75% vs 50%, P ϭ0.008) and had higher Charlson scores (33% vs 14% with score Ͼ4, P ϭ0.022) when compared to non-fungemic patients. Immune status categories are listed in Table 1 which shows that fungemic patients included 8 solid organ transplant (SOT) recipients (5 kidney, 1 kidney/ pancreas, and 2 liver), while non-fungemic patients included 3 SOT recipients (2 kidney, and 1 liver). HIV patients in both groups had CD4 counts Ͻ50 cells/mm 3 . Fungemic patients had a signifi cantly lower peripheral WBC (42% vs 9% WBCϽ3000 cells/mm 3 , P Ͻ0.001), hemoglobin (Hb) (40% vs 11% HbϽ10, P Ͻ0.001), platelets (plts) (58% vs 12% pltsϽ150,000 cells/mm 3 , P Ͻ0.001) and serum albumin (alb) (31% vs 13% albϽ3.5 g/dl, P ϭ0.018). They also had signifi cantly higher aspartate aminotransferase (AST) (43% vs 13% ASTՆ60, P ϭ0.001) and alkaline phosphatase (AlkP) serum concentrations (62% vs 17% AlkPՆ250, P Ͻ0.001).
The rates of positive bone marrow (89% vs 22%, P ϭ0.001) and urine cultures (45% vs 7%, P ϭ0.025) were signifi cantly higher in patients with concomitant H. capsulatum fungemia. Urine Histoplasma antigen test results were signifi cantly more positive in fungemic patients (81% vs 50%, P ϭ0.012), but no statistical differences were found between the two groups with respect to CSF and serum histoplasma antigen levels. Overall survival was not different between the 2 groups (Log Rank 0.366).
(CSF) antigen measured by radioimmunoassay (RIA) prior to 1997 and enzyme immunoassay (EIA) thereafter. Histoplasmosis serology, done by either complement fi xation (CF) or immunodiffusion (ID) methodology was considered positive at Ն1:8 and/or identifi cation of H or M bands but was not used as a diagnostic criterion in the absence of at least one of the other criteria listed above. Patients were excluded if; they declined research authorization at the time of initial evaluation, were initially diagnosed with histoplasmosis prior to 1 January 1991 and had a relapse episode during the study period, or had inactive histoplasmosis (i.e., no symptoms of infection but histopathologic identifi cation of organisms resembling H. capsulatum ) [ 10 ] . Patient data were retrieved by review of medical records. We calculated the Charlson score as a clinical comorbidity index. The Charlson score was originally designed as a measure of the risk of 1-year mortality attributable to comorbidity in a longitudinal study of general hospitalized patients, and then validated for the same outcome in a cohort of breast cancer patients. Its contents and weighting scheme were created on the basis of Cox proportional hazards modeling. Subsequently, it was adapted to the International Classifi cation of Diseases (ICD-9-CM) diagnosis and procedure codes [ 13, 14 ] .
Baseline characteristics for the fungemic and nonfungemic groups were compared using the two sample independent 't' test for continuous variables and chi square test for categorical variables. For non-parametric variables, Mann Whitney test was obtained. To identify risk factors for H. capsulatum fungemia, univariate and multivariable logistic regression were used. Based on previously published data [ 3 ] and our clinical impression, the following variables were included in the regression analysis: age Ն55 years, immunocompromise; Charlson score Ͼ4; peripheral white blood cell count (WBC) Ͻ3000 cells/ mm 3 ; and albumin Ͻ3.5 g/dl. Receiver operating curve revealed In-hospital mortality and relapse/second episode also did not differ among the 2 groups. Fungemic patients, however, were signifi cantly more likely to be hospitalised at presentation (76% vs 41%, P Ͻ0.001) and had longer hospital stays (13 vs 7 days, P ϭ0.023) than did controls.
Both univariate analysis and multivariate logistic regression were used to identify risk factors for H. capsulatum fungemia. In univariate analysis ( Table 2 ) we noted that immunocompromise (OR 2.9, P ϭ0.008), peripheral leukocyte count (WBC)Ͻ3000 cells/mm 3 (OR 7.3, P Ͻ0.001), albuminϽ3.5 g/ dl (OR 3.1, P ϭ0.018), and Charlson score of Ͼ4 (OR 2.9, P ϭ0.022) were associated with H. capsulatum fungemia but patient age of Ն55 years was not (OR 1.4, P ϭ0.38). In multivariable analysis, immunocompromise (OR 2.4, P ϭ0.043) and peripheral WBCϽ3000 cells/mm 3 (OR 6.5, P ϭ0.001) continued to be signifi cantly associated with H. capsulatum fungemia. Furthermore, there was a graded risk of fungemia noted with specifi c categories of immunocompromise ( Table 3 ) . As compared to immunocompetent patients with histoplasmosis, those with hematologic malignancy/stem cell transplantation, solid organ transplantation, and HIV not on HAART were 4, 5, and 10 times, respectively, more likely to have H. capsulatum fungemia. While other immunocompromised patients had twice the risk of fungemia as compared to the controls, the P value was not signifi cant.
Discussion
The current study describes our experience with H. capsulatum fungemia over a 15-year period. The relatively large number of H. capsulatum fungemia cases at Mayo Clinic allowed us to conduct a risk factor analysis of such infections which, to our knowledge, has not been previously described in the literature. We found that immunocompromise and peripheral WBCϽ3000 cells/ mm 3 were independent risk factors for the development of H. capsulatum fungemia among patients from whom blood samples were drawn for fungal culture. In addition, we were able to determine the strength of association between different conditions or treatments that contribute to immunocompromise status and H. capsulatum fungemia . HIV-infected patients not receiving HAART, solid organ and stem cell transplant recipients were found to be patients at highest risk. early death, respectively. Perhaps AIDS patients have specifi c characteristics other than low peripheral WBC that are critical for the development of severe disease. Our patient population included HIV-infected patients but also others patients who were immunocompromised due to other factors, including organ transplantation and malignancy. Among the other endemic mycosis, lymphocytopenia was shown to correlate with risk of dissemination of coccidioidomycosis [ 17 ] . Survival (91% vs 91%, P ϭ1), in-hospital mortality (9% vs 7%, P ϭ0.742), and relapse/second episode of histoplasmosis (11% vs 5%, P ϭ0.442) were not different between the two groups. Fungemic patients were signifi cantly more likely to be hospitalized at presentation (76% vs 41%, P Ͻ0.001) and to have a longer hospital stay (13 vs 7 days, P ϭ0.023) than did non-fungemic patients. The outcomes were possibly affected by a more aggressive treatment regimen and closer follow-up that was prompted by the complicating fungemia. A total of 40 cases (73%) vs 17 controls (30%) received an amphotericin B as part of the treatment regimen ( P Ͻ0.001), whereas itraconazole was the treatment chosen in 14 cases (25%) vs 24 controls (43%) ( P ϭ0.053). However, a chi square test showed no association between blood culture results and the type of initial antifungal therapy ( P ϭ0.275). If survival was affected by the selected treatment regimen, then use of validated risk factors for fungemia would assist in the early identifi cation and initiation of empiric aggressive treatment to hopefully improve survival rates.
A change in the standard operating procedure for ordering fungal blood cultures at our institution could have potentially impacted the fi ndings of this study. Prior to 1 November 2000, all blood culture ordered at Mayo Clinic automatically included bacterial and fungal cultures. After this date, fungal blood cultures were not automatically initiated for each blood culture request and a separate order for fungal blood cultures had to be provided. This change could potentially result in a selection bias because the clinicians would have to initiate an additional order. We do not think, however, that this impacted our results because the rates of fungal blood cultures obtained among patients Immunocompromise is a known risk factor for DH. In the outbreak study, immunocompromised patients were on corticosteroids or cytotoxic drugs, HIV infected, solid organ transplant recipients, or had hematologic malignancy, solid tumor, asthma, or sarcoidosis [ 3 ] . In that study, individual immunocompromise categories were not examined as separate entities to determine if there were graded risks to the different conditions due to the limited number of patients in each category. More recent reports of histoplasmosis in solid organ transplant recipients, cancer patients, and those on immunosuppressive medications, including TNF alpha inhibitors, did not include a statistical analysis for risk factors [ 8 -12 ] .
All HIV patients in both of our cohorts had extremely low CD4 counts (Ͻ50 cells/mm 3 ). The risk of developing H. capsulatum fungemia was lower in patients who were receiving HAART as compared to those who were not on this combination of medications. These results parallel fi ndings from previous studies [ 4 5 ] in which HIV patients receiving HAART were less likely than patients not on HAART to develop histoplasmosis [ 4 ] and had a better response to antifungal therapy and lower mortality among those who developed DH [ 5 ] .
In the current study, age was not detected as a risk factor for fungemia. The two patient groups had a similar mean age and the cut off age of Ն55 years was not a signifi cant risk factor in univariate and multivariate analyses. In the initial study by Wheat et al . [ 3 ] where age Ͼ54 years was found to be a risk factor for DH, the cohort was comprised of residents in an outbreak in Indianapolis. Perhaps under non-outbreak conditions where there is a broad temporal range of exposure to H. capsulatum , factors other than age may be operative in the development of fungemia. In addition, the outbreak study [ 3 ] included children (8 of 61 patients were less than 10 years old) who might have infl uenced the age distribution.
In our analysis, peripheral WBCϽ3,000 cells/ mm 3 was a risk factor for H. capsulatum fungemia. Among AIDS patients, WBCϽ4,000 cells/mm 3 [ 6 ] and a peripheral neutrophil count Ͻ1,700 cells/mm 3 [ 16 ] have not been previously found to be a marker of severe histoplasmosis and diagnosed with histoplasmosis prior to and after 1 November 2000 were comparable (28% vs 24%, P ϭ0.369). Similarly, the rates of positive fungal blood cultures for H. capsulatum did not differ between the two time periods despite the difference in the standard operating procedure (48% vs 52%, P ϭ0.642).
There are several limitations in our investigation. It is a retrospective analysis that does not permit calculation of incidence or control for unknown variables. There is also a selection bias, i.e., among 438 patients with histoplasmosis, only 111 (25%) had fungal blood cultures done. The risk factors we identifi ed are attributable to only those patients for whom fungal blood cultures were initiated. In addition, this is a single center design with a patient population that mainly represents Minnesota and the neighboring states. For instance, most patients were Caucasians and there is possible under-representation of minority populations. This is in contrast to the population described in the Indianapolis outbreaks where 40% of patients were African Americans and this was identifi ed as a risk factor for fatal and systemic histoplasmosis by univariate analysis [ 3 ] . In addition, the number of patients with HIV and histoplasmosis was limited due to the relatively low prevalence of HIV in the upper Midwest area. In the quantitative risk factor analysis, the statistical analyses are weakened by small numbers of patients (0-8) in each subcategory of immunocompromised patients which accounted for the accompanying large 95% confi dence intervals.
In conclusion, risk factors for H. capsulatum fungemia include peripheral WBCϽ3000 cells/ mm 3 and immunocompromise. Patients with HIV not receiving HAART are at highest risk, followed by solid organ transplant recipients and patients with hematologic cancer or stem cell transplantation. Patients with these risk factors are not only more susceptible to histoplasmosis but also Histoplasma fungemia. This should necessitate more aggressive early therapy with an amphotericin B-containing product in an effort to improve morbidity and mortality in this patient population.
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